User login
Key clinical point: Tofacitinib improved disease activity outcomes and clinical manifestations in patients with psoriatic arthritis (PsA) who initiated and continued treatment with tofacitinib.
Major finding: At 6 ± 3 months of follow-up, 25.0% and 7.8% of patients achieved Clinical Disease Activity Index for PsA-defined low disease activity and remission, respectively, and 18.2% of patients achieved minimal disease activity. A substantial proportion of patients also reported the resolution of dactylitis (29.4%) and enthesitis (42.9%).
Study details: Findings are from an observational study including 222 patients with PsA from the CorEvitas PsA/Spondyloarthritis Registry who initiated treatment with tofacitinib, of whom 123 patients had 6 ± 3 months of follow-up.
Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer Inc. The other authors declared having ties with various sources, including Pfizer.
Source: Mease PJ, Young P, Fallon L, et al. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2024 (Jan 22). doi: 10.1007/s40744-023-00631-4 Source
Key clinical point: Tofacitinib improved disease activity outcomes and clinical manifestations in patients with psoriatic arthritis (PsA) who initiated and continued treatment with tofacitinib.
Major finding: At 6 ± 3 months of follow-up, 25.0% and 7.8% of patients achieved Clinical Disease Activity Index for PsA-defined low disease activity and remission, respectively, and 18.2% of patients achieved minimal disease activity. A substantial proportion of patients also reported the resolution of dactylitis (29.4%) and enthesitis (42.9%).
Study details: Findings are from an observational study including 222 patients with PsA from the CorEvitas PsA/Spondyloarthritis Registry who initiated treatment with tofacitinib, of whom 123 patients had 6 ± 3 months of follow-up.
Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer Inc. The other authors declared having ties with various sources, including Pfizer.
Source: Mease PJ, Young P, Fallon L, et al. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2024 (Jan 22). doi: 10.1007/s40744-023-00631-4 Source
Key clinical point: Tofacitinib improved disease activity outcomes and clinical manifestations in patients with psoriatic arthritis (PsA) who initiated and continued treatment with tofacitinib.
Major finding: At 6 ± 3 months of follow-up, 25.0% and 7.8% of patients achieved Clinical Disease Activity Index for PsA-defined low disease activity and remission, respectively, and 18.2% of patients achieved minimal disease activity. A substantial proportion of patients also reported the resolution of dactylitis (29.4%) and enthesitis (42.9%).
Study details: Findings are from an observational study including 222 patients with PsA from the CorEvitas PsA/Spondyloarthritis Registry who initiated treatment with tofacitinib, of whom 123 patients had 6 ± 3 months of follow-up.
Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer Inc. The other authors declared having ties with various sources, including Pfizer.
Source: Mease PJ, Young P, Fallon L, et al. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2024 (Jan 22). doi: 10.1007/s40744-023-00631-4 Source